Results 141 to 150 of about 34,012 (206)

Post-marketing safety surveillance of pneumococcal vaccines: a real-world pharmacovigilance study using the U.S. vaccine adverse event reporting system (VAERS) database. [PDF]

Front Cell Infect Microbiol
Zheng X, Liu M, Ding A, Zhang S, Wu L, Kong F, Sun W, Peng Y, Xi Y.   +8 more
europepmc   +1 more source

A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan

Miwa Haranaka, Joon Young Song, Kuo‐Chin Huang, Richard de Solom, Masako Yamaji, Kathleen McElwee, Mary Kline, Masakazu Aizawa, Yahong Peng, Ingrid L. Scully, Osamu Kogawara, William C. Gruber, Daniel A. Scott, Wendy Watson   +13 more
openalex   +1 more source

Concentration and High Avidity of Pneumococcal Antibodies Persist at Least 4 Years after Immunization with Pneumococcal Conjugate Vaccine in Infancy [PDF]

, 2013
Nina Ekström, Heidi Åhman, Arto A. Palmu, Sinikka Grönholm, Terhi Kilpi, Helena Käyhty   +5 more
openalex   +1 more source

Inflammatory Knee Reaction Mimicking Septic Arthritis Following Closely Spaced Pneumococcal Vaccines in a Pediatric Patient Undergoing Immunodeficiency Evaluation. [PDF]

Cureus
Soule SM, Huntsman A, Chandra S, Thorne T, Holmes S, McKinley K.   +5 more
europepmc   +1 more source

Pneumococcal Conjugate Vaccine, Polysaccharide Vaccine, or Both for Adults? We’re Not There Yet [PDF]

, 2009
Katherine L. O’Brien
openalex   +1 more source

Cost-Effectiveness Analysis of Pneumococcal Vaccines in the Pediatric Population: A Systematic Review. [PDF]

Healthcare (Basel)
Vo NX, Pham HL, Bui UM, Ho HT, Bui TT.
europepmc   +1 more source

Impact of Pneumococcal Conjugate Vaccines on the Incidence of Pneumonia in Hospitalized Children after Five Years of Its Introduction in Uruguay

, 2014
María Hortal, Miguel Estevan, Miguel Meny, Inés Iraola, Hilda Laurani   +4 more
openalex   +2 more sources

Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea [PDF]

, 2018
Min-Joo Choi, Shin-On Kang, Jin-Jeong Oh, Seong‐Beom Park, Min Ja Kim, Hee Jin Cheong   +5 more
openalex   +1 more source

Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate Vaccine Compared With the Recommended Pneumococcal Vaccines in Older Adults. [PDF]

Am J Prev Med
Smith KJ, Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK.   +6 more
europepmc   +1 more source

Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. <i>Vaccines</i> 2025, <i>13</i>, 192. [PDF]

Vaccines (Basel)
Omole T, Pelayo E, Weinberg AS, Chalkias S, Endale Z, Tamms G, Sterling TM, Good L, Shekar T, Johnson M, Banniettis N, Buchwald UK, Esteves-Jaramillo A.   +12 more
europepmc   +1 more source